Rhizen Pharmaceuticals
Business Services · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
726 Us Hwy 202 396 Ste 320, Bridgewater,...Phone Number
+41 325800175Website
www.rhizen.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Rhizen Pharmaceuticals
Rhizen Pharmaceuticals AG is a biopharmaceutical company focused on developing innovative medicines to combat cancer and inflammation. The company is engaged in clinical studies for its novel pipeline, including Tenalisib and RP12146, targeting various cancer types. With a strong emphasis on strategic partnerships and a proven leadership team, Rhizen aims to advance its assets through clinical phases and collaborate with global partners for commercialization. Established in 2008, Rhizen is committed to cutting-edge science and has accumulated numerous patents from its dedicated research efforts.Explore more
Rhizen Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rhizen Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Rhizen Pharmaceuticals
Funding: Get notified immidiatlly once Rhizen Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Rhizen Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Rhizen Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Rhizen Pharmaceuticals launches new products
Check out if Rhizen Pharmaceuticals is spiking on competitors!
Rhizen Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Rhizen Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Rhizen Pharmaceuticals
Compare insights from companies similar to Rhizen Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rhizen Pharmaceuticals
$6.1M
51-200
Private
-
-
ST
Satheesh ThappaliVice President, Corporate Quality & Information Systems
Company Profile Activity
Activity Insights
Rhizen Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rhizen Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rhizen Pharmaceuticals.
Rhizen Pharmaceuticals Tech Stack
A closer look at the technologies used by Rhizen Pharmaceuticals
Rhizen Pharmaceuticals News & Media
Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022
BASEL, Switzerland--(BUSINESS WIRE)--Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage biopharmaceutical company announced today that it is presenting promising interim data from an ongoing Ph2 trial of Tenalisib in locally advanced or metastatic breast cancer patients, at the ESMO Breast Cancer Meeting, in Berlin, Germany from May 3-5, 2022. This multi-center, randomized phase II study is being conducted in eastern Europe and is designed to assess TenalisibRhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
BASEL, Switzerland--(BUSINESS WIRE)--Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting. Rhizen’s poster presentations describe the preclinical chRhizen Pharmaceuticals AG anuncia la dosificación del primer paciente en un estudio de fase I/Ib de su novedoso inhibidor de PARP (RP12146) en pacientes con tumores sólidos avanzados
BASILEA, Suiza--(BUSINESS WIRE)--Rhizen Pharmaceuticals AG (Rhizen), una compañía biofarmacéutica privada en fase clínica centrada en la oncología y la inflamación con sede en Suiza, ha anunciado hoy que comenzó la dosificación en un ensayo multicéntrico de fase I/Ib para evaluar su nuevo inhibidor de la polimerasa (ADP-ribosa) (RP12146) en pacientes con tumores sólidos avanzados. Este estudio multicéntrico de fase I/Ib, que consta de dos partes, se lleva a cabo en Europa y fue diseñado paraRhizen Pharmaceuticals AG annuncia il dosaggio del primo paziente in uno studio di fase I/Ib del suo nuovo inibitore di PARP (RP12146) in pazienti con tumori solidi di grado avanzato
BASILEA, Svizzera--(BUSINESS WIRE)--Rhizen Pharmaceuticals AG (Rhizen), una società biofarmaceutica svizzera a capitale privato specializzata nell'oncologia e nel trattamento delle infiammazioni in fase clinica, ha annunciato oggi di aver avviato il dosaggio in una sperimentazione multicentrica di fase I/Ib per valutare il suo nuovo inibitore di poli (ADP-ribosio) polimerasi (PARP) (RP12146) in pazienti con tumori solidi in stadio avanzato. Il testo originale del presente annuncio, redatto nell
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rhizen Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Rhizen Pharmaceuticals AG is a biopharmaceutical company focused on developing innovative medicines to combat cancer and inflammation. The company is engaged in clinical studies for its novel pipeline, including Tenalisib and RP12146, targeting various cancer types. With a strong emphasis on strategic partnerships and a proven leadership team, Rhiz... Read More
